Encube Ethicals Said to Plan $317 Million India IPO This Month
THE SO WHAT
A $317M Mumbai IPO for Encube Ethicals is another data point that Indian public markets will finance scaled, specialized pharma rather than waiting for Western exits. Founders in India’s health and life sciences stack can underwrite more of their growth plans to domestic equity markets, not just global PE.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureIndia-based EloElo, whose Story TV microdrama app has 33M+ estimated active users, raised an $80M Series C from Hornbill Capital and NBCU at a $500M valuation
EloElo pulling in $80M at a $500M valuation on 33M+ active users shows microdrama is solidifying as a mainstream format in India, not a fad. Global media and brands should be treating this as a testbed for short-form, serialized IP and commerce experiments, not just another social app.
These college students launched a legal tech startup during finals week. Now, it's business first, school second.
Student founders prioritizing a legal tech startup over grades is a reminder that talent is willing to trade credential safety for speed when the wedge is clear. If you’re hiring or partnering in legal services, don’t underestimate how quickly these “side projects” can become credible workflow vendors.
Startups & VentureFounders make terrible employees — here’s why every startup should hire them
The “founders make terrible employees” trope misses the point—repeat founders bring pattern recognition and bias for action that many scaling teams lack. If you’re past product-market fit, selectively hiring ex-founders into ambiguous, cross-functional roles can shorten decision cycles, as long as you’re explicit about autonomy and scope.
Startups & VentureDeeptech VCs are still too risk-averse with spinouts, and it’s costing them, say Europe’s leading spinout investors
If Europe’s best spinout investors think deeptech VCs are still too cautious, it means a lot of frontier IP is being underfunded or pushed abroad. Operators near universities should treat this as an arbitrage opportunity—partner early with labs and spinouts while capital is still mispriced.